Campylobacter jejuni and Campylobacter coli are among the most frequently isolated causes of bacterial diarrhea worldwide (40, 41), and C. jejuni has been recognized as an important cause of diarrhea in both travellers and deployed military personnel (11, 15, 28, 36) . Moreover, C. jejuni is the infectious agent most often associated with Guillain-Barre syndrome (GBS), a postinfectious polyneuropathy (2).
Campylobacter jejuni and Campylobacter coli are among the most frequently isolated causes of bacterial diarrhea worldwide (40, 41) , and C. jejuni has been recognized as an important cause of diarrhea in both travellers and deployed military personnel (11, 15, 28, 36) . Moreover, C. jejuni is the infectious agent most often associated with Guillain-Barre syndrome (GBS), a postinfectious polyneuropathy (2) .
There are several reports indicating that prior infection with C. jejuni can result in acquisition of immunity (8, 27) . However, development of vaccines has been hampered by a lack of understanding of the basic virulence mechanisms and by the antigenic complexity of these organisms. For example, the serotyping scheme developed by Lior et al. (23) is based on heat-labile antigens and has over 100 recognized serogroups. Although the serodeterminant of this scheme was originally thought to be flagellin (44) , genetic studies have indicated flagellin is not the serodeterminant in most serogroups (3) . The heat-stable serotyping scheme of Penner and Hennessy (35) , which is thought to be based on lipopolysaccharides (LPS), has over 70 serotypes. The LPS cores of many serotypes have been shown to contain sialic acid in structures which resemble human gangliosides (30) . This molecular mimicry has been implicated in the development of autoantibodies leading to GBS, although the specific structure or structures which enable a given campylobacter strain to cause GBS are not clear.
A formalin-fixed whole-cell vaccine of C. jejuni 81-176 adjuvanted with mutant E. coli heat-labile enterotoxin (LT R192G [12] ) is currently undergoing human testing (38, 42) . This formulation appears to offer protection against homologous challenge in animal models (6, 7) , but the ability to protect against multiple serotypes of C. jejuni remains to be determined. Moreover, given the lack of understanding about the pathogenesis of Campylobacter-associated GBS, there are concerns about use of whole-cell preparations of campylobacters as vaccines. This concern becomes more compelling if multiple strains, which are less well characterized than strain 81-176, were to be combined in order to generate broad cross-serotype-specific protection. An alternate approach would be to utilize a single campylobacter protein, either as a recombinant subunit vaccine or expressed in a carrier vaccine strain, to elicit protection against multiple Campylobacter serotypes. One candidate for inclusion among such vaccines is flagellin. Flagellin is the immunodominant antigen recognized during infection (9, 10, 32) , and development of antibodies against flagellin correlates with the development of protection against disease (27) . The structure of campylobacter flagellin contains both highly conserved and highly variable regions (25, 37) , in addition to glycosyl posttranslational modifications (14, 17, 39) . In this study we explore the use of a truncated recombinant flagellin, which includes the most highly conserved domains, as a subunit vaccine against campylobacters in two mouse models.
MATERIALS AND METHODS
Bacterial strains. C. jejuni 81-176 (Lior 5; O:27) and C. coli VC167 T2 (Lior 8 ; O:untypeable) have been described previously (8, 16, 18, 26, 37) . E. coli DH5␣ was the host for cloning experiments.
Molecular biology methods. DNA restriction enzymes and T4 DNA ligase were purchased from New England Biolabs (NEB; Beverly, Mass.) and used as recommended by the supplier. The maltose-binding protein (MBP) fusion vector, pMal-p2, was also purchased from NEB. Plasmid DNAs were routinely isolated by use of Qiagen columns (Qiagen, Chatsworth, Calif.).
DNA sequence analysis. Double-stranded plasmid DNAs were sequenced on an Applied Biosystems (ABI) model 373 DNA sequencer by using dideoxy terminator chemistry and Taq cycle sequencing kits (Perkin-Elmer/Applied Biosystems, Foster City, Calif.). The malE primer (5Ј-GGTCGTCAGACTGTCGA TGAAGCC-3Ј) was purchased from NEB. Primers for the sequence analysis of the flaA gene of strain 81-176 were synthesized on an ABI model 392 DNA synthesizer.
Purification of recombinant protein. Purification schemes were essentially as recommended by NEB. DH5␣ containing the flagellin-MBP fusion was grown overnight in 10 ml of rich medium (10 g of tryptone, 5 g of yeast extract, 5 g of NaCl, and 2 g of glucose/liter) supplemented with 100 g of ampicillin per ml and used to inoculate a fresh 1-liter culture of the same medium. This culture was grown with shaking at 37°C to an optical density at 600 nm of 0.5, and IPTG (isopropyl-␤-D-thiogalactoside; Gibco, Gaithersburg, Md.) was added to a final concentration of 0.3 mM. Cells were grown for an additional 2 h and harvested by centrifugation. Cells were resuspended in 10 ml of column buffer (20 mM Tris-Cl, 200 mM NaCl, 1 mM EDTA) per g (wet weight). The cells were frozen at Ϫ20°C overnight, thawed in iced water, and sonicated in an ice bath in short pulses for 2 min (Branson, Danbury, Conn.) or until the maximum amount of protein, as determined by Bio-Rad assay (Hercules, Calif.), was released. The sonicated solution was centrifuged for 30 min at 9,000 ϫ g in a Sorvall RC5-B centrifuge, and the supernatant was diluted 1:5 with column buffer and loaded onto a 2.5-by 10-cm glass column packed with 15 ml of amylose resin (NEB) at a flow rate of 1 ml/min. The column was washed with 12 volumes of column buffer, and the fusion protein was eluted with column buffer containing 10 mM maltose. Protein-containing fractions (as determined by the Bio-Rad assay) were pooled, concentrated with a centrifugal vacuum concentrator (Jouan, Winchester, Va.), and stored in aliquots at Ϫ20°C.
Electrophoresis and Western blotting. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed with a mini-slab gel apparatus (Pharmacia, Piscataway, N.J.) by the method of Laemmli (21) . Protein samples solubilized in sample buffer (21) were separated in 12.5% acrylamide (150 V) and either stained with Coomassie brilliant blue or transferred to nitrocellulose for immunological detection as previously described (22) . Rabbit hyperimmune serum E288 against SDS-denatured VC167 T2 flagellin was described previously (37) . Immunodetection was as described by Power et al. (37) . The secondary antibody for rabbit antisera was alkaline phosphatase-tagged goat anti-rabbit immunoglobulin G (IgG; Caltag, Burlingame, Calif.) used at a final dilution of 1:5,000; the secondary antibody for ferret antisera was horseradish peroxidaselabelled goat anti-ferret IgG (Kirkegaard and Perry, Gaithersburg, Md.) used at a dilution of 1:500. Alkaline phosphatase-tagged antibodies were developed with NBT-BCIP (Nitro Blue Tetrazolium plus 5-bromo-4-chloro-3-indolylphosphate; Promega, Madison, Wis.), and peroxidase-labelled antibodies were developed with TMB (3,3Ј,5,5Ј-tetramethylbenzidine; Sigma, St. Louis, Mo.).
Purification of flagellin. Flagellins were purified from Campylobacter spp. by the method of Power et al. (37) .
Immune animal sera. Immune ferret sera were obtained from a collection of sera at The Naval Medical Research Center-Food and Drug Administration from experiments in which ferrets were fed either VC167 T2 or 81-176 and subsequently developed diarrhea (13, 46) .
Immune human sera. Immune human sera from volunteers fed strain 81-176 were the generous gift of David Tribble of The Naval Medical Research Center.
Hyperimmune rabbit antiserum. Antiserum against the MBP-FlaA fusion was generated in a New Zealand White rabbit by intramuscular injection of 80 g of MBP-FlaA in 1 ml of Freund complete adjuvant, followed by a boost of the same material in Freund incomplete adjuvant 2 weeks later. The animal was exsanguinated 2 weeks after the second injection, and the resulting antiserum was designated LL1.
ELISA. MaxiSorp 96-well immunoplates were coated with MBP-FlaA or flagellins purified from campylobacters (0.3 g/ml, 100 l/well). Enzyme-linked immunosorbent assays (ELISAs) were performed as previously described (6) . Helicobacter-free BALB/c mice (6 to 8 weeks old) were purchased from Jackson Laboratory (Bar Harbor, Maine). The animals were housed in laminar-flow cages for a minimum of 7 days before being used in experiments. During this time fecal samples were routinely cultured as described below to be certain the animals were free of campylobacter. Standard laboratory chow and water were provided ad libitum. Mice were anesthetized with methoxyflurane (Metofane; Pitman-Moore, Mundelein, Ill.) and immunized intranasally with 30 to 35 l of fusion protein by using a micropipette. The doses used were 0, 3, 6, 12, 25, or 50 g of fusion protein in phosphate-buffered saline (PBS), either alone or in combination with 5 g of the genetically modified heat-labile enterotoxin of E. coli, designated LT R192G (12) as an adjuvant. A second dose was administered 8 days after the first vaccination. Intestinal lavage was collected 7 days after the second vaccination and blood was collected 21 days after the second vaccination as described earlier (7).
Challenge of immunized mice intranasally. C. jejuni 81-176 was grown for mouse challenge as described previously (7). Mice were intranasally challenged with 2 ϫ 10 9 bacteria/mouse 26 days after the second vaccination, and the animals were monitored for sickness and death for 5 days (7). An illness index was determined by assigning a score of 0 (apparently healthy), 1 (ill as determined by a hunched back, ruffled fur, and/or lethargy), or 2 (death) for each mouse daily (7) . For each observation day the total score within each group was divided by the number of mice observed to yield the daily index. Fecal excretion of C. jejuni was monitored daily for 10 to 14 days after challenge by culturing fecal homogenates (ca. 5% suspension in PBS) onto a campylobacter-selective agar (CVA; Remel, Lenexa, Kans.). Putative campylobacter colonies were confirmed by morphology and oxidase reactions. Challenge of immunized mice orally. Mice were challenged orally (5) with 0.5 ml of various doses of C. jejuni 81-176 grown as previously described (7). Fecal excretion was monitored as described above for 7 to 9 days.
Vaccine efficacy. Vaccine efficacy was calculated as follows: ([rate for control mice Ϫ rate for vaccinated mice]/rate for control mice) ϫ 100.
Statistical analysis. Comparisons of rates were done by using the Fisher exact test, and the comparisons of means used the Student t test.
Nucleotide sequence accession number. The DNA sequence of the strain 81-176 flaA gene has been deposited in GenBank under accession no. AF14052.
RESULTS

Construction and characterization of a flagellin-MBP fusion.
A portion of the flaA gene of VC167 T2 (16, 26) was amplified by PCR by using primers flaA-11 (5Ј-ACCAATAT TAACACAAATGTTGCAGCA-3Ј) and flaA-2 (5Ј-TTATCT AGACTAATCTCTACCATCATTTTTAAC-3Ј). The first 9 bp of flaA-11 include the recognition site of SspI; upon cleavage of the PCR product with SspI the 5Ј end of the PCR product corresponds to codon ATT encoding amino acid 5 of flaA (I). The 5Ј end of flaA-2 allows for the addition of an XbaI site 3Ј to bp 1015 of the coding region of flaA. The PCR product of this reaction was digested with SspI and XbaI, purified by agarose gel electrophoresis, and cloned into pMal-p2 which had been digested with XmnI and XbaI. The junction of the insert and vector in several appropriately sized plasmid DNAs was sequenced with the malE primer to confirm that the fusion was correct. One plasmid which contained the expected fusion to malE was termed pEB11-2 and was further characterized.
The apparent M r of the protein produced by DH5␣ (pEB11-2) was approximately 80,000, as determined by SDS-PAGE (Fig. 1A, lane 3) . This is consistent with the predicted M r of 79,687 for a fusion protein which includes M r 34,678 of FlaA and M r 45,009 from MBP. The fusion protein was immunoreactive with the anti-flagellin antiserum E288 (Fig. 1B, lane  3) and with anti-MBP antibody (data not shown). Polyclonal hyperimmune rabbit antiserum made against the MBP-FlaA (LL1) was also reactive with the fusion protein and native flagellin from both VC167 and 81-176, as seen in Fig. 1C .
DNA sequence analysis of the flaA gene of C. jejuni 81-176. The flaA gene of C. jejuni 81-176 has been cloned previously, and the 5Ј end has been partially sequenced (45) . The intact flaA gene of 81-176 as cloned in pK2-32 (45) was sequenced in order to determine the extent of similarity between the VC167 FlaA protein and that of 81-176 which would represent the challenge strain in protection experiments (see below). The results indicate that the flaA gene of 81-176 encodes a protein of 574 amino acids with a predicted M r of 59,240. Figure 2 compares FlaA sequences from strains VC167 T2 and 81-176. Overall, the two proteins are 92% identical and 94% similar. VC167 T2 flagellin has 573 amino acids with a predicted M r of 59,047 (16) . The region of the VC167 T2 FlaA which is included in the MBP-FlaA recombinant protein is underlined (amino acids 5 to 337). This region includes those amino acids which appeared to be the most immunogenic by mimeotope analysis (37) . The VC167 and 81-176 flagellins are 98.1% identical and 98.7% similar in this region. The homology is lowest between amino acids 382 and 471. In this region, which includes an additional amino acid in the 81-176 protein, the two flagellins are 73% identical and 84% similar. Comparison of the region of VC167 T2 flagellin in the MBP-FlaA fusion protein with 11 other C. jejuni flagellins (20, 29, 33 ) revealed a range of 82 to 90% identity and 89 to 96% similarity (data not shown).
Evaluation of immunoreactivity of MBP-FlaA with sera from animals experimentally infected with campylobacters.
The ability of sera from ferrets which had been previously infected with C. jejuni 81-176 or VC167 T2 (13, 45) to recognize the MBP-FlaA fusion protein was evaluated by ELISA. The results, summarized in Table a Animals were infected with between 10 9 and 10 10 cells of the indicated strains, and serum samples were taken 1 week after infection. An animal was considered to respond to the antigen if there was a Ͼ4-fold increase in titer compared to the preimmune sera.
adjuvant. Table 2 shows the intestinal IgA and serum IgG responses to MBP-FlaA as measured by ELISA. The full range of MBP-FlaA doses elicited significant antigen-specific serum IgG responses in vaccinated animals, and these responses were enhanced by adjuvant use, with the exception of the highest dose (50 g). In contrast, stimulation of FlaA-specific intestinal secretory IgA (sIgA) responses required immunization with higher doses of MBP-FlaA (Ն25 g) or coadministration of lower doses with adjuvant. When given with the adjuvant, as little as 3 g of the MBP-FlaA protein was capable of stimulating a significant antigen-specific sIgA response in immunized animals. In addition, the magnitude of intestinal sIgA responses to the recombinant protein were significantly enhanced in animals receiving the adjuvanted protein compared to those given MBP-FlaA alone, with the exception of the highest dose.
The mice were challenged intranasally with C. jejuni 81-176 (2 ϫ 10 9 bacteria/mouse) 26 days after the second immunization. The effects of the vaccine on disease symptoms and colonization on day 7 are summarized in Table 2 . The mean disease indices for mice which had received no vaccine or LT R192G alone were 0.92 and 0.86, respectively. The disease index of mice receiving MBP-FlaA without adjuvant decreased as the dose of vaccine increased up to 50 g (disease index ϭ 0.37, reflecting 55.3% efficacy), although the results were not statistically significant. In all cases, except for the 3-g dose, the addition of LT R192G decreased the disease index compared to the corresponding dose of MBP-FlaA without LT R192G . A dose of 50 g of MBP-FlaA plus LT R192G achieved 81.1% efficacy in protection against disease (P Ͻ 0.001). In previous experiments, when mice which had been infected intranasally with live 81-176 were rechallenged 26 days later with the same strain, there was 71% efficacy against disease symptoms (7) .
There was no effect on the numbers of mice colonized with strain 81-176 at any dose of MBP-FlaA without LT R192G except at the highest dose (50 g), which showed 47.6% efficacy in protecting against colonization. Similarly, mice receiving the lower doses of MBP-FlaA plus LT R192G showed little to no reduction in colonization. However, a dose of 50 g of MBPFlaA plus LT R192G resulted in 84.1% efficacy against colonization (P Ͻ 0.05). In previous experiments with this model, infection of mice with live 81-176 resulted in 91% efficacy against colonization after a second challenge with the same strain (7) .
Evaluation of the ability of MBP-FlaA to protect against colonization after oral feeding of mice. To better examine the ability of MBP-FlaA to protect against intestinal colonization, additional mice were vaccinated with two doses each of 50 g of MBP-FlaA with or without 5 g of LT R192G adjuvant; the doses were given 8 days apart. Twenty-six days after the second immunization, groups of seven to eight mice were challenged orally with three different doses of 81-176: 8 ϫ 10 10 , 8 ϫ 10 9 , or 8 ϫ 10 8 . Control animals immunized with either PBS or LT R192G alone were colonized throughout the course of the experiment regardless of the challenge dose. These results are shown in Fig. 3A for the high-dose challenge group only. Animals immunized with MBP-FlaA alone showed an apparent transient and insignificant reduction in total numbers colonized at days 5 and 6 (71.4% of the animals were culture positive) in the high-dose challenge group only (Fig. 3A) . However, on day 7 100% of the mice immunized with MBP-FlaA alone were colonized. When animals immunized with MBPFlaA plus LT R192G were challenged with 8 ϫ 10 10 organisms, there was a marked difference between the controls at days 5 to 7, with only 40% of the animals being colonized on days 5 and 6 (P Ͻ 0.05) and 20% being colonized on day 7 (P Ͻ 0.001; Fig.  3A) . This corresponds to a 55.2% efficacy for days 5 and 6 and a 71.4% efficacy for day 7. The efficacy improved when the animals were challenged with 8 ϫ 10 9 bacteria (Fig. 3B) . In this case, a significant difference between MBP-FlaA plus LT R192G versus MBP-FlaA alone and control groups was apparent by day 5, with the MBP-FlaA plus LT R192G vaccine giving 55.1% efficacy (P Ͻ 0.05). By day 7 only 28.6% of the animals in this group remained (71.4% efficacy; P Ͻ 0.001). Challenge of the MBP-FlaA plus LT R192G group with 8 ϫ 10 8 bacteria showed a significant reduction in colonization by day 4 (P Ͻ 0.05) and a drop in bacterial counts throughout the course of the experiment (Fig. 3C) . By day 6, the MBP-FlaA plus LT R192G vaccine resulted in 78% efficacy against colonization (P ϭ 0.001), and by day 7 no campylobacters could be detected in the stools under the sampling conditions used (P Ͻ 0.001).
DISCUSSION
The data presented here indicate that MBP-FlaA, when adjuvanted with LT R192G , is capable of eliciting a protective immune response against a heterologous strain of campylobacter as measured in two mouse models involving oral and nasal challenge. At the highest dose (50 g of MBP-FlaA plus 5 g of LT R192G ) the vaccine showed 81% protective efficacy against disease and 84% efficacy against colonization of the intestine in the mouse intranasal challenge model (7) . In this model, immunization with live 81-176, followed by a second infection with the same strain, resulted in 71% efficacy against disease and 91% efficacy against colonization (7) . Although the mouse intranasal model uses an unnatural route of infection, it is the only mouse model for campylobacter which consistently results in disease symptoms, these being generally pneumonia and bacteremia (7) . Intestinal colonization presumably occurs in this model when the mice swallow some portion of the infecting bacteria. To more directly measure the protection against colonization, we also challenged mice which had undergone the same immunization regimen (50 g of MBP-FlaA plus LT R192G ) with different oral doses of 81-176. The results showed that, when challenged with 8 ϫ 10 8 bacteria, there was a reduction in colonization as early as 3 days after infection and that no campylobacters could be detected in stools by 7 days postfeeding.
Flagella are a key virulence determinant of Campylobacter spp. since motility is essential for the establishment of colonization in the mucus lining of the gastrointestinal tract (22, 31, 34, 43) . Moreover, flagellin is an immunodominant antigen recognized during infection (9, 10, 27, 32) , and it has been suggested that the development of antibodies against flagellin correlates with the development of protection (11, 27, 32) . The observation that feeding of one strain of campylobacter protects against disease from the homologous, but not heterologous, strains (8) is consistent with the idea that the major protective antigen shows variation among strains. Although there is no flagellar serotyping scheme for campylobacters comparable to the H-antigen typing scheme of the Enterobacteriaceae, there is serological diversity among campylobacter flagellins (18, 25, 37) . In Salmonella spp. and E. coli it has been demonstrated that the amino and carboxy ends of flagellins are involved in the transport of the monomer and assembly into the filament, and these regions are highly conserved among serotypes. The central region of the flagellin protein, which lacks functional constraints, is the antigenically diverse region responsible for H serospecificity and is also the region which is surface exposed in the flagellar filament. Based on comparison of DNA sequence analyses of flagellin genes from several strains of C. jejuni, including that of strain 81-176 reported here, and one strain of C. coli (16, 20, 26, 29, 32, 33) , the overall structure of campylobacter flagellins appears to be similar to those of the enteric bacteria. Thus, the amino-and carboxy-terminal regions are highly conserved among campylobacter flagellins, and the central regions are more variable (19) . Moreover, Power et al. (37) have shown that antibodies to the amino and carboxy regions are not surface exposed in the flagellum filaments of campylobacters. The only antibodies found in that study to be surface exposed in the filament were those which recognize a glycosyl posttranslational modification (14, 17, 39) . These modifications alter the apparent M r of flagellins on SDS-PAGE gels. For example, the masses of the flagellins of strains VC167 and 81-176 are predicted to differ by only 207, but their apparent difference on SDS-PAGE is greater (Fig. 1) . Moreover, Alm et al. (4) showed that the apparent M r of flagellin can vary when expressed in different campylobacter hosts. The presence of a carbohydrate moiety on a bacterial flagellin is highly unusual and has been shown to confer serospecificity to the flagellin (14) . Thus, antisera which recognize the posttranslational modifications on the flagellar filament of VC167 (Lior 8) also react with the flagellins of other strains of Lior 8 but not with those of strains from other Lior serogroups (4). Although flagellin is not the serodeterminant of Lior 8 (i.e., nonflagellated mutants of Lior 8 strains still serotype), flagellins appear to be conserved antigenically within the serogroup. Moreover, more recent studies have suggested that glycosyl modifications on flagellin, as well as other campylobacter proteins, are immunodominant (39) .
One would expect that any protective epitopes would be surface exposed on the flagellar filament. The role of these surface-exposed posttranslational modifications on protection has been addressed in only one study with the RITARD (removable intestinal tie adult rabbit diarrhea) model. In this model, protection against colonization appeared to be limited to strains of the same Lior serotype. In other words, immunization by feeding with VC167 protected rabbits against subsequent colonization after RITARD challenge with the homologous strain, as well as challenge with two other C. jejuni strains of the Lior 8 serogroup, but not against strains of other serogroups (17) . A site-specific mutant defective in a gene required for biosynthesis of the posttranslational modification in VC167 was capable of protecting against a challenge of wild-type VC167 but not the other C. jejuni Lior 8 strains, suggesting that the posttranslational modifications are responsible for this Lior 8 serospecific protection. Given this data, one would not expect that recombinant flagellin that lacked the posttranslational modifications, which are encoded by other campylobacter genes, would be protective, but the data presented here suggest otherwise. In this regard, it is interesting that antibodies generated during natural infection in ferrets by either strain 81-176 or strain VC167 appeared to react more strongly to glycosylated flagellins isolated from Campylobacter spp. than to unglycosylated, recombinant flagellins isolated from E. coli. Similar analysis with serum from a human volunteer who had been infected with 81-176 (42) also suggested a stronger immune response to native flagellin than to recombinant flagellin. Although the recombinant construction used contains a truncated FlaA, this region was selected based on its high immunogenicity in a mimeotope mapping study (37) . Thus, the lack of immune response to this region with antisera from experimentally infected humans and animals was surprising and suggests that during natural gastrointestinal infection the immunodominant epitopes are those of the posttranslational modifications rather than of the primary amino acids.
Immunization with the recombinant fusion protein lacking these posttranslational modifications may lead to antibody production against epitopes which are less immunogenic in the native molecule due to differences in folding and/or masking by the carbohydrate moiety but are, nonetheless, capable of eliciting a protective immune response. We are currently further evaluating this recombinant flagellin as a vaccine in a ferret diarrheal disease model (13, 46) .
